Day One Biopharmaceuticals develops targeted therapies to treat people with life-threatening diseases.
Day One Biopharmaceuticals has raised $175.0M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in July 2024.
Day One Biopharmaceuticals's investors include Franklin Templeton, RA Capital Management, Wellington Management, Canaan Partners, Janus Henderson Investors.
Day One Biopharmaceuticals is headquartered in South San Francisco, United States.
Day One Biopharmaceuticals develops targeted therapies to treat people with life-threatening diseases.
Day One Biopharmaceuticals is at the Post-IPO Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Day One Biopharmaceuticals — Funding & Investors." VCBacked, July 30, 2024, https://www.vcbacked.co/company/day-one-biopharmaceuticals. Accessed August 14, 2026.
VCBacked. (2024). Day One Biopharmaceuticals — Funding & Investors. Retrieved August 14, 2026, from https://www.vcbacked.co/company/day-one-biopharmaceuticals
{{cite web |title=Day One Biopharmaceuticals — Funding & Investors |url=https://www.vcbacked.co/company/day-one-biopharmaceuticals |website=VCBacked |access-date=August 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated